Diaceutics PLC (LON:DXRX – Get Free Report) insider Nick Roberts purchased 112 shares of Diaceutics stock in a transaction dated Monday, September 30th. The shares were purchased at an average cost of GBX 134 ($1.79) per share, for a total transaction of £150.08 ($200.75).
Nick Roberts also recently made the following trade(s):
- On Wednesday, August 28th, Nick Roberts acquired 113 shares of Diaceutics stock. The shares were acquired at an average cost of GBX 134 ($1.79) per share, for a total transaction of £151.42 ($202.54).
Diaceutics Price Performance
LON DXRX opened at GBX 133.50 ($1.79) on Thursday. The company has a debt-to-equity ratio of 2.93, a quick ratio of 9.92 and a current ratio of 4.85. The stock has a market cap of £112.77 million, a price-to-earnings ratio of -4,433.33 and a beta of 0.58. The business has a 50 day simple moving average of GBX 128.91 and a 200 day simple moving average of GBX 120.31. Diaceutics PLC has a 52-week low of GBX 82 ($1.10) and a 52-week high of GBX 136 ($1.82).
Analyst Ratings Changes
Read Our Latest Analysis on Diaceutics
Diaceutics Company Profile
Diaceutics PLC, a diagnostic commercialisation company, provides data, data analytics, and implementation services for pharmaceutical companies worldwide. It operates DXRX platform, which offers DXRX data solutions, including access to various pipelines of diagnostic testing data from a network of laboratories that provides DXRX signal, lab mapping, testing dashboard, and physician mapping services; DXRX marketplace solutions, which enables a marketplace, where labs, pharma, and diagnostic companies come to find partners for collaborations on precision medicine diagnostics.
Featured Articles
- Five stocks we like better than Diaceutics
- What is a Bond Market Holiday? How to Invest and Trade
- S&P 500 Hitting Resistance: These 3 Stocks Offer the Best Upside
- How to Buy Cheap Stocks Step by Step
- Nike’s Post-Earnings Drop Presents a Buying Opportunity
- Best of the list of Dividend Aristocrats: Build wealth with the aristocrat index
- Microsoft’s Targeted Upside Might Be Too Good to Ignore
Receive News & Ratings for Diaceutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Diaceutics and related companies with MarketBeat.com's FREE daily email newsletter.